Method for egfr directed combination treatment of cancer

A method of treating a patient suffering from cancer driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), which cancer is selected from the group consisting of head and neck squamous cell carcinoma (HNSCC), malignant glioma, breast cancer, esophageal cancer, gastric cancer, renal cancer, cervical cancer, prostate cancer, ovarian cancer, pancreatic cancer, hepatocellular cancer, and colorectal cancer (CRC), including metastatic forms thereof,

• and
• wherein:
• the patient has a tumor expressing mutated forms of the EGFR, and the patient has acquired resistance to tyrosine kinase inhibitor (TKI) treatment,
• comprising administering to a patient in need of such treatment a flexible and active regimen for combining an irreversible tyrosine kinase inhibitor (TKI) and a Human EGFR targeted monoclonal antibody (mAB), wherein in this method the TKI is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly,
• wherein the method results in overcoming the acquired resistance to tyrosine kinase inhibitor (TKI) treatment.